P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
J. Kuruvilla,
P. Armand,
A. F. Herrera,
V. Ribrag,
P. Brice,
C. Thieblemont,
B. Von Tresckow,
E. Kim,
P. Marinello,
S. Chakraborty,
R. Orlowski,
P. L. Zinzani
Affiliations
J. Kuruvilla
1 Princess Margaret Cancer Centre, Toronto, Canada
P. Armand
2 Dana-Farber Cancer Institute, Harvard Medical School, Boston
A. F. Herrera
3 City of Hope Medical Center, Duarte, United States of America
V. Ribrag
4 Institut Gustave Roussy, Villejuif
P. Brice
5 APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France
C. Thieblemont
5 APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France
B. Von Tresckow
6 University Hospital Cologne, University of Cologne, and West German Cancer Center, Essen University Hospital, University of Duisburg-Essen, Essen, Germany
E. Kim
7 Merck & Co., Inc., Kenilworth, United States of America
P. Marinello
7 Merck & Co., Inc., Kenilworth, United States of America
S. Chakraborty
7 Merck & Co., Inc., Kenilworth, United States of America
R. Orlowski
7 Merck & Co., Inc., Kenilworth, United States of America
P. L. Zinzani
8 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
